Therefore, telmisartan appears to inhibit NASH progression by PPARγ activation as well as by partial activation of PPARα and PPARδ through AGTR1 antagonism, resulting in down-regulation of genes related with inflammation and fibrosis in STAM mice. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.